Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Type 2 Diabetes Mellitus: Update Bulletin [October 2015]

Product Code:
596200439
Publication Date:
October 2015
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events that have the potential to shape the treatment of type 2 diabetes mellitus (T2DM). Topics covered include opinions on ITCA 650’s (exenatide, continuous subdermal delivery; Intarcia Therapeutics) potential role in the treatment of T2DM and reactions to its innovative delivery mechanism; new data for Bydureon (exenatide once weekly; AstraZeneca), and its potential impact on compliance; new Phase III data for LixiLan (insulin glargine plus lixisenatide; Sanofi), and how its efficacy compares to Xultophy (insulin degludec plus liraglutide; Novo Nordisk); the potential impact of data from the EMPA-REG OUTCOME trial which showed that Jardiance (empagliflozin; Eli Lilly/Boehringer Ingelheim) provides a protective benefit against cardiovascular events; the potential of oral semaglutide (NN-9924; Novo Nordisk) as a treatment for T2DM, and expectations for its recently announced Phase III programme; the potential impact of biosimilar versions of insulin, and discounting strategies for Abasaglar (insulin glargine; Eli Lilly/Boehringer Ingelheim) in the UK.

Key Questions Answered in this Update Bulletin:

  • Based on the data from the Phase III FREEDOM-2 study, how will Intarcia Therapeutics’ ITCA 650 (exenatide, continuous subdermal delivery) be used and what products will it displace in the treatment of type 2 diabetes mellitus?
  • Will ITCA 650 improve compliance, and are there are any lingering concerns about the potential safety of the drug due to its innovative delivery mechanism?
  • What do KOLs think about Phase II data for Novo Nordisk’s orally active formulation of semaglutide, and what are the expectations for the Phase IIIa study?
  • What do KOLs think of the new data suggesting that AstraZeneca’s Bydureon (exenatide, once weekly) might lower the risk of gastrointestinal adverse effects – thereby improving compliance – and how might this data impact the use of the product?
  • What do KOLs think about new Phase III data for Sanofi’s LixiLan (insulin glargine plus lixisenatide, fixed dose combination), and how does the efficacy demonstrated in Phase III compare to Novo Nordisk’s Xultophy (insulin degludec and liraglutide)?
  • What do KOLs think about the potential impact of data from the EMPA-REG OUTCOME trial which showed that Eli Lilly’s/Boehringer Ingelheim’s Jardiance (empagliflozin) provides a protective benefit against cardiovascular events?
  • How do KOLs believe the entrance of biosimilar versions of insulin, specifically insulin glargine, will impact prescribing habits, and what has been the reaction to the discounts being offered in the UK?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved